Results 151 to 160 of about 79,208 (292)

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real‐world evidence

British Journal of Haematology, EarlyView.
Summary Ruxolitinib remains first‐line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post‐ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis ...
Andrea Duminuco, Patrick Harrington, Elena Torre, Hillary Catellani, Novella Pugliese, Matteo Pacilli, Annalisa Santisi, Arianna Sbriglione, Giuseppe A. Palumbo   +8 more
wiley   +1 more source

JAK2 Gene [PDF]

, 2020
openaire   +1 more source

Estimated pulse wave velocity as a marker of major adverse cardiovascular events in essential thrombocythaemia and polycythaemia vera

British Journal of Haematology, EarlyView.
In patients with essential thrombocythaemia or polycythaemia vera, higher estimated pulse wave velocity (ePWV) was independently associated with major adverse cardiovascular events, while its relationship with overall survival was largely age‐driven.
Alessandro Costa, Olga Mulas, Federica Pilo, Eleonora Atzeni, Martina Pettinau, Daniela Mantovani, Giovanni Caocci   +6 more
wiley   +1 more source

Cardiovascularis szövődmények a JAK2 mutációval járó klonális myeloproliferatív eltérésekben

A JAK2 egy olyan onkogén, melynek aktivációja myeloproliferativ hematológiai kórképek mellett összefüggésbe hozható fokozott kardiovaszkuláris rizikóval is.
Magyar, Eszter
core  

Effect of EZH2 regulation of the JAK2/STAT3 signaling pathway on proliferation and apoptosis in non‑small cell lung cancer cells. [PDF]

Oncol Rep
Wu S, Zhang W.
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Dual-Driver Myeloproliferative Neoplasm: Concurrent p190 <i>BCR::ABL1</i> CML and <i>JAK2</i> V617F Mutation: A Case Report and Literature Review. [PDF]

Case Rep Hematol
Elkady M, Jin Y, Zhao W.
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source

Molecular Abnormalities and Associated Clinical Features in Polycythemia Vera. [PDF]

Med Sci (Basel)
Testa U, Castelli G, Pelosi E.
europepmc   +1 more source